Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.60 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.54 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.54 |
| ▸ | CYP4F2 | P78329 | 7/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 7/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14191031 | 0.87 | GPR119 (0.78) | GPR119PARP10PARP15CYP4F2CYP4A11 | |
| SCHEMBL3983198 | 0.85 | GPR119 (0.56) | GPR119CYP4F2CYP4A11 | |
| SCHEMBL4455486 | 0.83 | PARP10 (0.49) | GPR119PARP10PARP15CHEK2FFAR4 | |
| SCHEMBL18842731 | 0.79 | GPR119 (0.59) | GPR119PARP10PARP15CYP4F2CYP4A11 | |
| SCHEMBL15539598 | 0.78 | GPR119 (0.59) | GPR119PARP10PARP15CYP4F2CYP4A11 | |
| SCHEMBL16758109 | 0.78 | GPR119 (0.55) | GPR119PARP10PARP15CYP4F2CYP4A11 | |
| SCHEMBL18842722 | 0.78 | GPR119 (0.61) | GPR119PARP10PARP15CYP4F2CYP4A11 | |
| SCHEMBL15537613 | 0.77 | GPR119 (0.56) | GPR119PARP10PARP15CYP4F2CYP4A11 | |
| SCHEMBL16769051 | 0.77 | GPR119 (0.57) | GPR119PARP10PARP15CYP4F2CYP4A11 | |
| SCHEMBL15539206 | 0.77 | GPR119 (0.57) | GPR119CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059516-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (publ) (SE) | 2009-05-20 | — | — | EP | claimed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | claimed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | claimed |
| EP-2059516-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (publ) (SE) | 2009-05-20 | — | — | EP | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103123-A1 | New compounds | GPR119, GPR139, GPR180 | GPR119 1/4885PARP10 3463/4885PARP15 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.